BridgeBio Oncology merges with Helix Acquisition Corp. II in a $450M SPAC deal, securing $196M from trust account and $260M in PIPE financing led by Cormorant Asset Management.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.